Mocetinostat (MGCD0103) is a potent and isotype-selective inhibitor of histone deacetylases (HDACs). In cell-free assays, Mocetinostat (MGCD0103) exhibited most potent inhibition against human HDAC1 (IC50 = 0.15 ?M) and also has inhibitory activity against HDAC2, HDAC3, and HDAC11, with IC50 values ranged 0.3 to 1.7 ?M. No activity was showed on HDACs 4-8. [1] Mocetinostat (MGCD0103) exhibited potent inhibition activity in proliferation of human cancer cell lines, both in cell-based assay and in human tumor xenografts in nude mice. [1]
Mocetinostat (MGCD0103) has been evaluated in Phase II clinical trials in patients with metastatic leiomyosarcoma [2] and Hodgkin??s lymphoma [3]."

Mocetinostat (MGCD0103) is a potent and isotype-selective inhibitor of histone deacetylases (HDACs). In cell-free assays, Mocetinostat (MGCD0103) exhibited most potent inhibition against human HDAC1 (IC50 = 0.15 ?M) and also has inhibitory activity against HDAC2, HDAC3, and HDAC11, with IC50 values ranged 0.3 to 1.7 ?M. No activity was showed on HDACs 4-8. [1] Mocetinostat (MGCD0103) exhibited potent inhibition activity in proliferation of human cancer cell lines, both in cell-based assay and in human tumor xenografts in nude mice. [1]
Mocetinostat (MGCD0103) has been evaluated in Phase II clinical trials in patients with metastatic leiomyosarcoma [2] and Hodgkin??s lymphoma [3]."